Clinical Trial Update: Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial PANDA investigates a four-drug regimen (capecitabine, oxaliplatin, docetaxel, and atezolizumab) for resectable gastric and gastroesoph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• Taxotere (docetaxel)
• Tecentriq (atezolizumab)
• Xeloda (capecitabine)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Stomach Cancer, Gastro Esophageal Junction Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING